
Please try another search
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is engaged in developing products to improve the quality of life. It is focused on the development and commercialization of immunotherapies for cancer. The Company through OncoQuest Inc. offers a technology platform that includes a portfolio of tumor antigen-specific monoclonal immunoglobulins including CA-125, MUC1, PSA, and Her2/neu. Its product candidate CA-125 antibody is used in the treatment of ovarian cancer. Its anti-MUC1 antibody program is used in the treatment of breast cancer. It is engaged in developing antibody-based immunotherapeutic products for cancer in the Greater China territory. The Company is also developing an antibody, AR 9.6 mAb against truncated O-glycan on MUC16, for targeted cancer therapy applications.
Name | Age | Since | Title |
---|---|---|---|
Ki-Jun Hwang | - | 2005 | Member of Scientific Advisory Board |
Ronald Moore | - | 2005 | Member of Scientific Advisory Board |
Michael A. Hollingsworth | - | - | Member of Scientific Advisory Board |
Jeffrey Shon | - | 2021 | Independent Director |
Ragupathy Madiyalakan | - | 2004 | CEO & Director |
Christopher Nicodemus | - | 2010 | Chairman of Scientific Advisory Board |
Shawn Lu | 54 | 2015 | Independent Director |
John Mark Lievonen | - | 2021 | Independent Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review